Document is current

Article History

Received: 9 November 2022

Revised: 27 March 2023

Accepted: 5 April 2023

First Online: 5 May 2023

Declarations

:

: This study was approved by the Ethics Committee of the canton Berne (registration number 2021–01341) based on the informed consent of all included patients to use their coded data for this retrospective analysis and performed in accordance with the International Council for Harmonisation E6 Good Clinical Practice Guideline, the 1964 Declaration of Helsinki and its later amendments, and federal laws.

: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. JGG acts as advisor and speaker for several pharmaceutical companies and contributes to several international industry-sponsored clinical studies in the fields of retinal disease and uveitis (AbbVie, Bayer, Novartis, Roche) which had no bearing on the underlying work. None of the authors have conflicting interests with the data that are presented herein.